BenevolentAI Investor Presentation Deck

PDE10 inhibition: potential to normalise dysregulated mechanisms in IBD Macrophage M₂ M1 Dendritic Cell INF-KB PGE₂ IL-12 IL-6 IL-18 IL-1B IL-23 TNF Th1 IFNY TNFO IL-2 ILC3 TIL-17A IL-22 Th17 IL-17A IL-17F IL-21 IL-22 IL-23 • Reduced inflammatory cytokine release from intestinal epithelia via ↓NFkB(¹) • Reduced tissue-resident macrophage activation (1) Reduced intestinal inflammation PDE10 inhibition ↑ CGMP ↑ CAMP Sources: (1) Harmel-Laws et al PLoS One 2013: (2) Han et al PLoS One 2011; (3) Brenna et al Scand J Gastroenterol 2015 Images: Nettleford and Prabhu, Antioxidants 2018 (left); He et al. Int J Mol Sci 2020 (right) Na Nutrients ptir myn ಬ MLCK PAMR fluid Nutrients claudins occludin MLCK TNF • Improved TJ assembly via PKG/PKA-mediated pMLC (2) • Improved fluid/mucus homeostasis via PKG phosphorylation of intestinal CFTR (3) Improved barrier integrity Benevolent 45

View entire presentation